BioPharma Dive November 15, 2024
The San Diego biotech made an unsolicited bid to buy Evotec. Elsewhere, BeiGene recast itself as BeOne Medicines in a change meant to reflect its commitment to oncology.
Today, a brief rundown of news involving Evotec, Bluebird bio and the company formerly known as BeiGene, as well as updates from Leerink Partners and Abeona Therapeutics that you may have missed.
Halozyme Therapeutics has made an unsolicited bid to buy drug discovery specialist Evotec for 11 euros per share in cash, an offer worth some 2 billion euros in total. In a press release, Halozyme said the combined company could offer increased scale and become a “highly attractive strategic partner” to the drug industry. Evotec, in its own statement, said it...
Today's Sponsors
Today's Sponsor